Found: 8
Select item for more details and to access through your institution.
In patients with primary Sjögren's syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1017157
- By:
- Publication type:
- Article
CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren's Syndrome.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.887972
- By:
- Publication type:
- Article
Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.
- Published in:
- Rheumatology, 2023, v. 62, n. 1, p. 243, doi. 10.1093/rheumatology/keac205
- By:
- Publication type:
- Article
CCR9/CXCR5 Co-Expressing CD4 T Cells Are Increased in Primary Sjögren's Syndrome and Are Enriched in PD-1/ICOS-Expressing Effector T Cells.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 15, p. 11952, doi. 10.3390/ijms241511952
- By:
- Publication type:
- Article
Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 24, p. 9544, doi. 10.3390/ijms21249544
- By:
- Publication type:
- Article
Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 2, p. 279, doi. 10.1002/art.42319
- By:
- Publication type:
- Article
The Transcriptomic Profile of Monocytes from Patients With Sjögren's Syndrome Is Associated With Inflammatory Parameters and Is Mimicked by Circulating Mediators.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.701656
- By:
- Publication type:
- Article
Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjögren's Syndrome Patients Identifies CCL5 as a Novel Effector Molecule.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.702733
- By:
- Publication type:
- Article